Title : Human butyrylcholinesterase polymorphism: Molecular modeling - Lushchekina_2015_Int.J.Risk.Saf.Med_27 Suppl 1_S80 |
Author(s) : Lushchekina SV , Delacour H , Lockridge O , Masson P |
Ref : Int J Risk Saf Med , 27 Suppl 1 :S80 , 2015 |
Abstract :
BACKGROUND: Prolonged apnoea following injection of ester-containing myoralaxants was first described in 1953. Because a large part of administered succinylcholine is shortly hydrolyzed by plasma butyrylcholinesterase (BChE) under normal conditions, prolonged apnoea was attributed to deficiency in BChE. It was found that BChE deficiency was due to genetic variations. Human BChE gene shows a large polyallelism. About 75 natural mutations of the BCHE gene have been documented so far [1]. Most of them cause alteration in BChE activity through point mutation effect on catalytic activity. Frame shifts and stop codons may also affect expression, or cause truncations in the sequence. OBJECTIVE: Recently, two novel BChE "silent" variants, Val204Asp [2] and Ala34Val [3], causing prolonged neuromuscular block after administration of mivacurium, were discovered. Mutations were genetically and kinetically characterized. The aim of the current study was to understand how these mutations determine "silent" phenotype. |
PubMedSearch : Lushchekina_2015_Int.J.Risk.Saf.Med_27 Suppl 1_S80 |
PubMedID: 26639724 |
Lushchekina SV, Delacour H, Lockridge O, Masson P (2015)
Human butyrylcholinesterase polymorphism: Molecular modeling
Int J Risk Saf Med
27 Suppl 1 :S80
Lushchekina SV, Delacour H, Lockridge O, Masson P (2015)
Int J Risk Saf Med
27 Suppl 1 :S80